Legend Biotech (LEGN) EBT Margin (2019 - 2025)
Legend Biotech (LEGN) reported EBT Margin of 6.4% for Q4 2025, down 1532.0% on a YoY basis from 0.45% in Q4 2024, and up 144.6% quarter-over-quarter from 14.35% in Q3 2025.
Legend Biotech (LEGN) EBT Margin (2019 - 2025) Analysis & Trends
Legend Biotech has reported EBT Margin for 7 years, with the latest figure at 6.4% in Q4 2025.
- For the quarter ending Q4 2025, EBT Margin fell 1532.0% year-over-year to 6.4%; the trailing twelve-month figure through Dec 2025 stood at 23.66% (up 155.0% YoY), and the FY2025 full-year result was 27.47%, down 5267.0% from the prior year.
- EBT Margin for Q4 2025 stood at 6.4%, up from 14.35% in the prior quarter.
- The five-year high for EBT Margin was 21.72% in Q4 2024, with the low at 1612.82% in Q2 2022.
- Historically, EBT Margin has averaged 238.81% across 5 years, with a median of 64.65% in 2023.
- Annual changes were most pronounced in 2022 — EBT Margin tumbled 116018 bps — and 2023, when it surged 134167 bps.
- Legend Biotech's EBT Margin stood at 226.53% in 2021, then tumbled by 117 bps to 491.16% in 2022, then jumped by 100 bps to 0.18% in 2023, then jumped by 11854 bps to 21.72% in 2024, then sank by 71 bps to 6.4% in 2025.
- The last three EBT Margin figures came in at 6.4% (Q4 2025), 14.35% (Q3 2025), and 48.93% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 6.40% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 41.95% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Regeneron Pharmaceuticals | 63.43 Bn | 54.67 Bn | 3.31 Bn | 23.05% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 6.40% |
| Sep 30, 2025 | -14.35% |
| Jun 30, 2025 | -48.93% |
| Mar 31, 2025 | -50.82% |
| Dec 31, 2024 | 21.72% |
| Sep 30, 2024 | -75.46% |
| Jun 30, 2024 | -9.63% |
| Mar 31, 2024 | -63.61% |
| Dec 31, 2023 | -0.18% |
| Sep 30, 2023 | -65.09% |
| Jun 30, 2023 | -271.16% |
| Mar 31, 2023 | -308.16% |
| Dec 31, 2022 | -491.16% |
| Sep 30, 2022 | -309.94% |
| Jun 30, 2022 | -1,612.82% |
| Mar 31, 2022 | -64.20% |
| Dec 31, 2021 | -226.53% |
| Sep 30, 2021 | -738.96% |
| Jun 30, 2021 | -452.64% |
| Mar 31, 2021 | -0.69% |